Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia
- PMID: 20425334
- DOI: 10.1007/s11899-006-0025-4
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia
Abstract
Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease. It is usually well tolerated and cheap and has been proven effective in many studies for the prevention of thrombohemorrhagic complications associated with these disorders. However, many clinicians are reluctant to use it because of the perceived risk of progression to acute leukemia. Several recent, large studies have given this drug a new lease on life. Relevant results from these studies are discussed, and the risk of leukemia is placed in perspective to demonstrate that hydroxyurea remains the drug of choice in patients with either of these disorders.
Similar articles
-
Treatment of the myeloproliferative disorders with 32P.Eur J Haematol. 2000 Jul;65(1):1-7. doi: 10.1034/j.1600-0609.2000.9r119.x. Eur J Haematol. 2000. PMID: 10914933 Review.
-
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Am J Hematol. 1996 May;52(1):42-6. doi: 10.1002/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6. Am J Hematol. 1996. PMID: 8638610
-
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.Ann Hematol. 2014 Dec;93(12):2037-43. doi: 10.1007/s00277-014-2152-7. Epub 2014 Jul 2. Ann Hematol. 2014. PMID: 24981691 Clinical Trial.
-
Treatment of polycythaemia vera and essential thrombocythaemia.Baillieres Clin Haematol. 1998 Dec;11(4):769-85. doi: 10.1016/s0950-3536(98)80038-3. Baillieres Clin Haematol. 1998. PMID: 10640216 Review.
-
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.Am J Hematol. 2012 Mar;87(3):285-93. doi: 10.1002/ajh.23135. Am J Hematol. 2012. PMID: 22331582 Review.
Cited by
-
Successful treatment of hydroxyurea-associated panniculitis and vasculitis with low-dose methotrexate.JAAD Case Rep. 2017 Sep 8;3(5):422-424. doi: 10.1016/j.jdcr.2017.06.009. eCollection 2017 Sep. JAAD Case Rep. 2017. PMID: 28932785 Free PMC article. No abstract available.
-
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.Pharmacol Res Perspect. 2025 Jun;13(3):e70109. doi: 10.1002/prp2.70109. Pharmacol Res Perspect. 2025. PMID: 40313042 Free PMC article.
-
Hyperkalaemia associated with hydroxyurea in a patient with polycythaemia vera.Eur J Clin Pharmacol. 2011 Jul;67(7):757-8. doi: 10.1007/s00228-010-0962-7. Epub 2010 Dec 14. Eur J Clin Pharmacol. 2011. PMID: 21153897 No abstract available.
-
Laser Photobiomodulation for a Complex Patient with Severe Hydroxyurea-Induced Oral Ulcerations.Case Rep Dent. 2016;2016:9810480. doi: 10.1155/2016/9810480. Epub 2016 Nov 10. Case Rep Dent. 2016. PMID: 27957350 Free PMC article.
-
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.Clin Epigenetics. 2013 Jul 30;5(1):12. doi: 10.1186/1868-7083-5-12. Clin Epigenetics. 2013. PMID: 23898968 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources